Certolizumab Pegol and Secukinumab for Treating Active Psoriatic Arthritis after Inadequate Response to DMARDS (TA445)

Apremilast for Treating Active Psoriatic Arthritis (TA433)

Certolizumab Pegol for Treating Rheumatoid Arthritis after Inadequate Response to a TNF-Alpha Inhibitor (TA415)

Secukinumab for Active Ankylosing Spondylitis after Treatment with Non-Steroidal Anti-Inflammatory Drugs or TNF-Alpha Inhibitors (TA407)

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus (TA397)

TNF-Alpha Inhibitors for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis (TA383)

Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis Not Previously Treated with DMARDs or after Conventional DMARDs Only Have Failed (TA375)

Abatacept, Adalimumab, Etanercept and Tocilizumab for Treating Juvenile Idiopathic Arthritis (TA373)

Ustekinumab for Treating Active Psoriatic Arthritis (TA340 [rapid review of TA313])

Rituximab in Combination with Glucocorticoids for Treating Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (TA308)

Table: Vitamin D3 Supplements

Formulations and indications of colecalciferol preparations.

Table: DMARDs, a Guide to Monitoring Requirements

Tests for patients on disease-modifying arthritis drugs.